EP1608359A4 - Tumor-targeting drug-loaded particles - Google Patents

Tumor-targeting drug-loaded particles

Info

Publication number
EP1608359A4
EP1608359A4 EP04758803A EP04758803A EP1608359A4 EP 1608359 A4 EP1608359 A4 EP 1608359A4 EP 04758803 A EP04758803 A EP 04758803A EP 04758803 A EP04758803 A EP 04758803A EP 1608359 A4 EP1608359 A4 EP 1608359A4
Authority
EP
European Patent Office
Prior art keywords
tumor
targeting drug
loaded particles
loaded
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04758803A
Other languages
German (de)
French (fr)
Other versions
EP1608359A2 (en
Inventor
Jessie L-S Au
M Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1608359A2 publication Critical patent/EP1608359A2/en
Publication of EP1608359A4 publication Critical patent/EP1608359A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
EP04758803A 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles Withdrawn EP1608359A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46082703P 2003-04-03 2003-04-03
US460827P 2003-04-03
PCT/US2004/010230 WO2004089291A2 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles

Publications (2)

Publication Number Publication Date
EP1608359A2 EP1608359A2 (en) 2005-12-28
EP1608359A4 true EP1608359A4 (en) 2011-08-17

Family

ID=33159807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04758803A Withdrawn EP1608359A4 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles

Country Status (8)

Country Link
EP (1) EP1608359A4 (en)
JP (1) JP4927535B2 (en)
KR (1) KR100849911B1 (en)
CN (2) CN1816331B (en)
AU (1) AU2004228008B2 (en)
CA (1) CA2520475C (en)
IL (1) IL171185A (en)
WO (1) WO2004089291A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
WO2006103112A2 (en) * 2005-03-31 2006-10-05 Lidds Ab Method for treating prostate diseases based on local delivery of active substances
BRPI0600285C1 (en) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda nanoparticulate pharmaceutical compounds useful for treating restenosis
JP2007277217A (en) * 2006-03-17 2007-10-25 Fujifilm Corp Biodegradable matrix homogeneously encapsulating medicament
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
EP2241342A3 (en) * 2006-11-20 2011-01-12 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
EP2074988B1 (en) 2007-12-28 2018-03-14 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009116556A1 (en) * 2008-03-19 2009-09-24 富士フイルム株式会社 Pharmaceutical composition for injection
ES2462090T5 (en) 2008-06-16 2017-07-12 Pfizer Inc. Polymeric nanoparticles loaded with drug and manufacturing processes and use thereof
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (en) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド Long-circulating nanoparticles for sustained release of therapeutic agents
ES2721898T3 (en) 2009-12-11 2019-08-06 Pfizer Stable formulations to lyophilize therapeutic particles
EA201290499A1 (en) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. COMPOSITIONS OF THERAPEUTIC POLYMER NANOPARTICLES WITH HIGH GLASSING TEMPERATURE AND HIGH-MOLECULAR CO-POLYMERS
KR101314579B1 (en) * 2011-04-07 2013-10-10 광주과학기술원 Paclitaxel- loaded polymeric nanoparticle and preparation thereof
JP2013053103A (en) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd Liver-accumulative nanoparticle having drug encapsulated therein
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
BR112015005940A2 (en) 2012-09-17 2017-07-04 Bind Therapeutics Inc process for the preparation of therapeutic nanoparticles
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
RS56362B1 (en) 2013-09-16 2017-12-29 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
PL3116547T3 (en) 2014-03-14 2019-11-29 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2016111913A1 (en) * 2015-01-05 2016-07-14 Boston Scientific Scimed, Inc. Biodegradable drug eluting microsphere for the treatment of solid tumors
AU2016270559B2 (en) 2015-06-04 2020-12-10 Crititech, Inc. Collection device and methods for use
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CN106075535B (en) * 2016-06-14 2019-04-02 武汉纺织大学 A kind of medical dressing and preparation method thereof
WO2018011040A1 (en) * 2016-07-13 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases
WO2018067545A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis
CN107049984A (en) * 2017-03-14 2017-08-18 武汉理工大学 A kind of preparation method for carrying taxol polylactic-co-glycolic acid microballoon
KR102024273B1 (en) * 2017-03-27 2019-11-04 주식회사 피에프디 Device and method for drug action management
JP2020523285A (en) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド Treatment of epithelial cysts by intracystic injection of antitumor particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
RU2020110399A (en) 2017-10-03 2021-11-09 Крититек, Инк. LOCAL DELIVERY OF ANTITUMOR PARTICLES IN COMBINATION WITH SYSTEM DELIVERY OF IMMUNOTHERAPY AGENTS FOR CANCER TREATMENT
JP2021509663A (en) * 2018-01-05 2021-04-01 クリティテック・インコーポレイテッド Treatment of bladder cancer by topical administration of taxane particles
GB201800912D0 (en) * 2018-01-19 2018-03-07 Ucl Business Plc Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
US20190365698A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
EP3750524A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Delayed and sustained delivery of anticancer drugs
EP3750523A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Active substance delivery system
WO2022075318A1 (en) * 2020-10-08 2022-04-14 学校法人関西医科大学 Evaluation marker reflecting efficacy of cancer treatment composition
US20240016774A1 (en) * 2020-10-14 2024-01-18 Foundry Therapeutics, Inc. Implantable depots for localized, sustained, controlled release of therapeutic agents to treat cancer and related conditions
US20240307220A1 (en) * 2021-03-05 2024-09-19 H. Lee Moffitt Cancer Center And Research Institute Inc. Combination Therapy to Treat Temperature Sensitive Mutant Tumors
CN115770224B (en) * 2023-01-17 2023-04-18 中国人民解放军总医院第一医学中心 Acrylic acid microsphere carrying paclitaxel medicine and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021908A1 (en) * 1997-10-29 1999-05-06 Angiotech Pharmaceuticals, Inc. Polymeric systems for drug delivery and uses thereof
US20020013298A1 (en) * 1996-12-02 2002-01-31 William L. Hunter Compositions and methods for treating or preventing inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2369263A1 (en) * 1999-04-09 2000-10-19 Jessie Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6444227B1 (en) * 1999-08-05 2002-09-03 Roche Vitamins Inc. Process for preparing fat soluble beadlets
JP2004516262A (en) * 2000-12-21 2004-06-03 ネクター セラピューティクス Induced phase transition method for the production of microparticles containing hydrophilic activators
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013298A1 (en) * 1996-12-02 2002-01-31 William L. Hunter Compositions and methods for treating or preventing inflammatory diseases
WO1999021908A1 (en) * 1997-10-29 1999-05-06 Angiotech Pharmaceuticals, Inc. Polymeric systems for drug delivery and uses thereof

Also Published As

Publication number Publication date
AU2009200463A1 (en) 2009-03-05
CA2520475A1 (en) 2004-10-21
CN1816331B (en) 2012-08-08
CA2520475C (en) 2012-10-09
EP1608359A2 (en) 2005-12-28
KR20060006911A (en) 2006-01-20
KR100849911B1 (en) 2008-08-04
CN102697737B (en) 2014-03-19
JP2006522148A (en) 2006-09-28
WO2004089291A3 (en) 2005-04-21
JP4927535B2 (en) 2012-05-09
WO2004089291A2 (en) 2004-10-21
AU2004228008A1 (en) 2004-10-21
AU2004228008B2 (en) 2008-11-06
IL171185A (en) 2013-07-31
CN102697737A (en) 2012-10-03
CN1816331A (en) 2006-08-09

Similar Documents

Publication Publication Date Title
IL171185A (en) Tumor-targeting drug-loaded particles
EP1616881A4 (en) Anti-mpl antibodies
DK1889621T3 (en) MULTI PARTICLES
AU2003293294A1 (en) Uv-stabilised particles
IL175608A0 (en) Antibodies
GB2401547B (en) Particulate materials
IL176165A0 (en) Cffdinir oral suspension
HK1075221A1 (en) Electrostatic filter construction
GB0223127D0 (en) nanoparticles
GB2398241B (en) Particle formation
GB0316695D0 (en) Particle formation
EP1699435A4 (en) Particles
GB0223149D0 (en) Nanoparticles
GB0402043D0 (en) Differential
GB0324147D0 (en) Functionilisation of particles
GB0300338D0 (en) Particle formation
GB0201382D0 (en) Virus-like particles
GB0229662D0 (en) Nanostructures
GB0518478D0 (en) Particles
AP2059A (en) Heavy particle separation
GB0329208D0 (en) Particulate materials
AU2009200463B2 (en) Tumor-Targeting Drug Loaded Particles
ZA200408974B (en) Pesticidal particle
GB0321873D0 (en) Particles
GB0328397D0 (en) Particles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087013

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110714

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20110708BHEP

Ipc: A61K 31/704 20060101ALI20110708BHEP

Ipc: A61K 31/337 20060101ALI20110708BHEP

Ipc: A61K 9/51 20060101ALI20110708BHEP

Ipc: A61K 9/50 20060101ALI20110708BHEP

Ipc: A61K 9/16 20060101ALI20110708BHEP

Ipc: A61K 9/00 20060101ALI20110708BHEP

Ipc: A61K 31/335 20060101AFI20110708BHEP

17Q First examination report despatched

Effective date: 20120507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1087013

Country of ref document: HK